AUS
NZ
UK
CA
USA
IND
Resonance Health Limited (ASX:RHT), a leading Australian healthcare technology and services provider, has revealed its full-year FY26 financial results, highlighting strong operational progress across its three main business segments. The company recorded a net positive operating cash inflow of $2.9 million for the year, supported by total cash receipts of $14.3 million, and ended the quarter with a net cash position of $2.3 million. Contributions from clinical trial management, software-as-medical-device imaging analysis, and clinical trial site services, alongside key pharmaceutical partnerships and an enhanced balance sheet, position Resonance Health for growth in FY27.
Key Highlights
- Resonance Health Limited (ASX:RHT) delivers clinical trial management, imaging analysis software, and clinical trial site services globally from Australia.
- Achieved positive operating cash flow in every quarter of FY26, with full-year cash receipts totaling $14.3 million and net operating cash inflow of $2.9 million.
- Quarter-end cash at bank rose to $4.8 million, offset by $2.5 million in bank debt, resulting in a net cash position of $2.3 million, up from $1.8 million as of 31 March 2026.
- Completed recruitment for a $13.8 million major pharmaceutical clinical trial in April 2026; patient milestones are triggering invoicing throughout FY27.
- Software-as-Medical Device (SaMD) forward orders and bid pipeline exceed $12 million, with multiple contract renewals and new wins secured during the quarter.
- Expanded TrialsWest clinical trial site network with the Mandurah location, opened in July 2025, performing ahead of expectations and nearing breakeven in its first year.
- Completed recruitment for a Non-Invasive MRI Liver Fibrosis Extended-Proof-of-Concept trial; data analysis is underway and expected to conclude within three months.
FY26 Positive Operating Cash Flow Reflects Strong Operational Efficiency Across All Quarters
Resonance Health’s consistent positive operating cash flow throughout all four quarters of FY26 marks a notable operational milestone. The company generated a net positive operating cash inflow of $2.9 million for the full year, supported by $14.3 million in customer cash receipts. This steady quarterly cash conversion highlights the company’s effectiveness in turning revenue into operating cash across its diversified offerings, including clinical trial management, software-as-medical-device imaging analysis, and clinical trial site services.
The final quarter of FY26 recorded $4.0 million in cash receipts and a net positive operating cash inflow of $0.7 million, sustaining the year-long momentum. This achievement is significant given the multi-divisional nature of the business and the varying revenue timing typical of clinical trial and pharmaceutical service operations. It demonstrates efficient working capital management and cash conversion across Resonance Clinical, SaMD, and TrialsWest units.
Major Pharmaceutical $13.8 Million Clinical Trial Achieves Full Recruitment
During the quarter, Resonance Clinical reached a key milestone by completing recruitment for a major pharmaceutical clinical trial valued at $13.8 million, initially announced in November 2024. The division successfully enrolled all 60 targeted patients, setting the stage for sustained revenue recognition in the latter half of FY26 and into FY27. As patients meet study completion milestones, invoicing events are expected to continue, providing clear revenue visibility.
This recruitment completion validates Resonance Clinical’s expertise in managing complex, large-scale pharmaceutical trials and reinforces its value to major pharma clients. The division is actively pursuing new opportunities from existing and new customers, with several bids currently under review. Its proven execution capability positions it well for contract expansions and increased engagement within pharmaceutical and therapeutic development sectors.
Software-as-Medical Device Division Surpasses $12 Million Pipeline Amid Clinical Trial Revenue Growth
The Software-as-Medical Device division showed robust market traction during the quarter, securing new contracts and extensions with global pharmaceutical customers. Forward orders and the bid pipeline now exceed $12 million, providing multi-year revenue visibility and supporting sustainable growth forecasts. The division’s proprietary imaging analysis products, including AI-powered devices such as FerriSmart, HepaFatSmart, and LiverSmart, continue to gain adoption among pharmaceutical companies conducting clinical trials requiring quantitative medical imaging.
Clinical trial revenue in the SaMD division increased markedly compared to FY25, reflecting rising demand for non-invasive, MRI-based diagnostic and monitoring solutions. The portfolio, certified to ISO 13485 standards and cleared in the USA, Europe, UK, and Australia, offers a differentiated solution in a growing market. Multiple contract renewals and new wins during the quarter underscore ongoing customer confidence in Resonance Health’s imaging analysis and AI-driven assessment tools.
TrialsWest Clinical Trial Site Network Growth with Mandurah Location Exceeding Expectations
The TrialsWest clinical trial site services division continues to expand and deliver strong operational results. The Osborne Park clinic in Western Australia remains consistently profitable, nearing its original annualised revenue target. The Mandurah clinic, opened in July 2025, is outperforming expectations with several trials underway and approaching breakeven within its first year. This rapid ramp-up highlights strong pharmaceutical customer demand and effective site management.
TrialsWest’s performance is driven by sustained demand from pharmaceutical clients for dependable clinical trial site services. The division is exploring additional locations and therapeutic areas to support further growth, positioning itself for scalable expansion. The profitability of Osborne Park combined with Mandurah’s ahead-of-plan results demonstrates the replicability and scalability of the TrialsWest model across multiple regions, enabling ongoing revenue and margin growth.
Advancement of Non-Invasive Liver Fibrosis MRI Device Through Extended-Proof-of-Concept Trial
Resonance Health’s development of a Non-Invasive MRI Liver Fibrosis device progressed with the completion of recruitment for its Extended-Proof-of-Concept trial during the quarter. Data analysis is currently underway, with validation expected to follow based on analytical outcomes. The company anticipates completing data analysis within three months, which will inform regulatory planning and commercialization pathways. This timeline supports potential near-term regulatory submissions and customer adoption pending successful trial results.
Following positive Extended-Proof-of-Concept results, the company plans to advance regulatory planning by enabling existing customers to use the product as an investigational endpoint alongside biopsy in clinical trials. This strategy leverages established customer relationships and provides real-world validation. The development aligns with global demand for safer, more efficient non-invasive liver fibrosis diagnostics, positioning Resonance Health in a growing hepatology assessment market.
Balance Sheet Strengthened with Net Cash Position Increasing to $2.3 Million
During FY26, Resonance Health improved its balance sheet, increasing cash at bank from $3.0 million at 30 June 2025 to $4.8 million at 30 June 2026. Bank debt under the National Australia Bank facility stood at $2.5 million at quarter-end, resulting in a net cash position of $2.3 million, up from $1.8 million at 31 March 2026. The company repaid $0.3 million in borrowings during FY26 while simultaneously growing cash reserves, reflecting disciplined capital management and reduced leverage.
This stronger net cash position enhances financial flexibility to pursue strategic growth initiatives in FY27 without relying on external capital or additional debt. Combined with consistent positive operating cash flow and recent board enhancements, Resonance Health is well positioned to invest internally in clinic network expansion, product development, and business development. The company’s cash generation trajectory and declining debt support its strategy to fund growth organically.
Board Enhancements Support Strategic Growth Plans for FY27
Resonance Health strengthened its Board during the period, with new members expected to improve governance and strategic oversight for FY27 initiatives. Managing Director and CEO Andrew Harrison emphasized the importance of the enhanced Board in supporting the company’s next growth phase. These governance improvements coincide with the company’s improved financial position and operational momentum across all divisions.
With a fortified Board, full-year positive operating cash flow, and an increasing net cash position, Resonance Health is well equipped to pursue strategic growth in FY27. Enhanced governance, strong cash flow, and reduced financial constraints provide management with the capacity to evaluate and execute expansion opportunities, including additional TrialsWest clinics, new SaMD product developments, and expanded clinical trial management services. The company remains focused on growing its three core business areas, supported by FY26 operational and financial achievements.
Regulatory Approvals and Product Portfolio Strengthen Global Market Presence
Resonance Health’s regulatory-cleared Software-as-Medical Device portfolio offers significant competitive advantages in global pharmaceutical and clinical markets. The suite includes FerriScan, the internationally recognized gold standard for liver iron concentration assessment, along with AI-enhanced products FerriSmart for automated real-time assessment, HepaFatScan for non-invasive liver fat measurement, HepaFatSmart for multi-metric liver fat evaluation, and LiverSmart, the latest AI-driven multi-parametric device expanding clinical applications.
These products hold ISO 13485 certification and have received clearances from the FDA, European, UK, and Australian regulatory bodies. This multi-jurisdictional approval assures customers of product quality and clinical utility across regions. Resonance Health’s scientific rigor and regulatory compliance establish it as a trusted provider of quantitative medical assessments essential for disease management and pharmaceutical development. The broad regulatory-cleared portfolio and AI integration position the company at the forefront of advanced medical imaging analysis solutions.
Industry Trends and Market Demand Fuel Ongoing Expansion Opportunities
Resonance Health operates within healthcare sectors benefiting from strong structural tailwinds supporting growth. Global pharmaceutical companies increasingly require sophisticated clinical trial infrastructure and services to efficiently advance drug development. The shift toward non-invasive, AI-enabled diagnostics in hepatology, cardiology, and other areas aligns with Resonance Health’s core offerings. Worldwide regulatory acceptance of AI-enabled medical devices expands market opportunities for established providers with proven compliance.
The company’s three-division model delivers diversified revenue streams while focusing on clinical trial and pharmaceutical services. Growing demand from pharmaceutical customers for imaging analysis, clinical trial site services, and trial management reflects broader industry trends toward outsourcing and specialization. Market expansion potential exists across geographies, therapeutic areas, and customer segments, supported by regulatory credentials and demonstrated clinical value. Resonance Health’s role as a key service provider to pharmaceutical and clinical research sectors offers revenue stability and growth potential as it executes its strategic initiatives.
